达必妥(Dupilumab)Duumab是一种新型的生物制剂,被广泛用于治疗多种免疫相关疾病,如特异反应性皮炎、哮喘、嗜酸性食管炎和结节性痒疹。下面,我们将详细介绍达必妥(Dupilumab)Duumab在国内上市的时间及其相关疾病的治疗效果。 1. 特异反应性皮炎(Atopic Dermatitis) 特异反应性皮炎是一种慢性、复发性皮肤炎症疾病,常表现为...
Methods AA patients with and without concomitant atopic dermatitis were randomized 2:1 to receive weekly subcutaneous dupilumab (300 mg) or placebo for 24 weeks, followed by another 24-week dupilumab open-label phase. The primary outcome was change from baseline in the Severity of Alopecia Tool ...
特异反应性皮炎(Atopic Dermatitis) 1. 特异反应性皮炎是一种慢性和复发性的皮肤炎症,表现为皮肤红肿、瘙痒和干燥。达必妥作为单克隆抗体,靶向IL-4和IL-13信号通路,已被证明在治疗特异反应性皮炎方面具有显著的疗效。 2. 疗效评估 多项临床试验显示,使用达必妥治疗特异反应性皮炎的患者在瘙痒、皮肤炎症、疾病严重程度...
EP.1:Atopic Dermatitis: A Form of Eczema EP.2:Differences in Atopic Dermatitis Clinical Presentation EP.3:Atopic Dermatitis: Early Referral to Dermatology Clinics EP.4:Non-Pharmacological Treatments for Atopic Dermatitis EP.5:Topical Treatments for Atopic Dermatitis ...
译文标题:Dupilumab改善了2至<18岁儿童患有难控制特应性皮炎的临床评分:一项单中心真实世界研究 原文摘要: Dupilumab is the first biologic agent approved for treatment of moderate to severe atopic dermatitis (AD). Phase 3 clinical trials have shown the efficacy and safety in AD children. However, real...
Eight phase 3 clinical studies evaluating dupilumab exposure among patients with atopic dermatitis were what the analysis was based upon. These data included findings from the LIBERTY AD SOLO 1, SOLO 2, CHRONOS, PEDS, ADOL, PRESCHOOL Part B, OLE, and PED-OLE studies. ...
10.Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial[J]. The Lancet, 2017, 389...
10.Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, doub...
10.Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial[J]. The Lancet, 2017, 389...
[1] AS P, EL S, EC S, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2022 Sep 17;400(10356):...